Rituximab Induction Is Cost Effective for Asymptomatic Advanced Follicular LymphomaMarch 23rd 2018
Rituximab induction therapy has the highest probability of cost effectiveness in treating newly diagnosed patients with asymptomatic advanced follicular lymphoma, according to a study published in the British Journal of Haematology.
Noninvasive Evaluation Can Help Determine Infliximab's Efficacy in IBDMarch 22nd 2018
In patients with IBD, it was found that gut microbial levels lack in diversity. After receiving infliximab treatment, CD patients restored their microbial diversity and increased their Clostridiales levels. Clostridiales reduced proinflammatory bacteria, produced short-chain fatty acids, and induced an immune response.
Study: Corticosteroid Use May Delay Initiation of Biologics in Patients With RAFebruary 22nd 2018
Patients with rheumatoid arthritis (RA) who use corticosteroids can delay the initiation of biologic disease-modifying antirheumatic drugs (DMARDs), have higher incidence of adverse events (AEs), and have more healthcare costs before the initiation of biologic DMARDs than patients who do not use corticosteroids.
Personalized Anti-VEGF Regimens Improve Adherence Among Patients With Macular DegenerationFebruary 7th 2018
Managed care professionals can assist ophthalmologists and retina specialists in personalizing anti-vascular endothelial growth factor (anti-VEGF) treatment to encourage patient adherence, according to a recent review of the literature on this topic.